Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2020 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Feb 7, 2020
Slide 1: Investor Presentation Q3FY20
Investor Presentation Q3FY20 February 7, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q3FY20 and 9MFY20
Key Highlights of Q3FY20 and 9MFY20 Strong quarter marked by healthy revenue growth and significant improvement in EBITDA margins • Revenue from Operations grew by 13.3% YoY during the quarter, accompanied by 450 bps YoY improvement in EBITDA margin • Profit After Tax for the quarter grew by 88.6% c
Slide 4: Key Financial Highlights – Q3FY20
Key Financial Highlights – Q3FY20 All figures in Rs mn Revenue from Operations India sales 14,239 12,475 21,818 19,263 Q3FY19 Q3FY20 International sales 7,253 6,532 Q3FY19 Q3FY20 Q3FY19 Q3FY20
Slide 5: Key Financial Highlights – Q3FY20
Key Financial Highlights – Q3FY20 All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 4,533 13,474 11,283 3,135 58.6% 61.8% 16.3% 20.8% Q3FY19 Q3FY20 Q3FY19 Q3FY20 PBT (before Minority Interest) PAT (after Minority Interest) 3,820 4,046 2,581 2,025 Q3FY19 Q3FY20 Q3FY19 Q3FY20
Slide 6: Key Financial Highlights
Key Financial Highlights 9MFY20 (Consolidated) Particulars (Rs mn) 9MFY20 9MFY19 YoY growth Revenue from Operations 62,954 55,042 14.4% Gross Profit 38,448 33,348 15.3% Gross Profit margin 61.1% 60.6% EBITDA 11,704 8,809 32.9% EBITDA margin 18.6% 16.0% PBT 10,245 7,559 35.5% PBT margin 16.3% 13.7% P
Slide 7: India Business
India Business India Business: Q3FY20 Sales of Rs.14,239 million (14.1% YoY growth) • India sales contributed 66.3% to total sales in Q3FY20 • In Q3FY20, Company’s secondary sales grew by 15.4% YoY - significantly ahead of the IPM growth of 9.6% YoY. Similarly in 9MFY20 also, the Company grew ahead
Slide 8: Secondary Sales Performance
Secondary Sales Performance Outperformance across most of the major therapeutic areas in Q3FY20 +1 Established therapeutic Market rank 1 3 3 4 areas of Alkem 20.8% 17.3% 12.1% 8.4% 9.7% 7.6% 7.0% 7.3% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growt
Slide 9: US Business
US Business US Business: Q3FY20 Sales of Rs.5,837 million (12.6% growth YoY) • US sales contributed 27.2% to total sales in Q3FY20 • The YoY growth in the US business during the quarter was mainly driven by new product launches • In Q3FY20, the Company filed 4 ANDAs with the US FDA and received 4 ap
Slide 10: Update on the US FDA inspection
Update on the US FDA inspection Facility Scope Last inspection Status post last inspection Baddi (India) Formulation August 2019 Successfully closed without any observations Daman (India) Formulation August 2019 EIR# received in October 2019, thereby successfully closing the inspection St. Louis (US
Slide 11: Other International Business
Other International Business Other International Business: Q3FY20 Sales of Rs.1,416 million (5.0% growth YoY) • Other International Market sales contributed 6.6% to total sales in Q3FY20 • The Company has presence in Australia, Europe, South East Asia, Latin America and Africa • Company’s key market
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 31, 2019 Non-Institution, 19.24% Institution, 14.72% Promoter & Promoter Group, 66.04% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 13: Thank You
a \ 08 ig Thank You ALKEM